These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 35935474)
1. COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study. Tang F; Hammel IS; Andrew MK; Ruiz JG Lancet Healthy Longev; 2022 Sep; 3(9):e589-e598. PubMed ID: 35935474 [TBL] [Abstract][Full Text] [Related]
2. Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data. Tang F; Hammel IS; Andrew MK; Ruiz JG J Nutr Health Aging; 2023; 27(2):81-88. PubMed ID: 36806862 [TBL] [Abstract][Full Text] [Related]
3. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222 [TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Nyberg T; Ferguson NM; Nash SG; Webster HH; Flaxman S; Andrews N; Hinsley W; Bernal JL; Kall M; Bhatt S; Blomquist P; Zaidi A; Volz E; Aziz NA; Harman K; Funk S; Abbott S; ; Hope R; Charlett A; Chand M; Ghani AC; Seaman SR; Dabrera G; De Angelis D; Presanis AM; Thelwall S Lancet; 2022 Apr; 399(10332):1303-1312. PubMed ID: 35305296 [TBL] [Abstract][Full Text] [Related]
5. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401 [TBL] [Abstract][Full Text] [Related]
6. Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Nacer-Laidi H; Azmi B; Palmer T; Giddings R; Fuller C; Irwin-Singer A; Baynton V; Tut G; Moss P; Hayward A; Copas A; Shallcross L Lancet Healthy Longev; 2022 Jul; 3(7):e470-e480. PubMed ID: 35813279 [TBL] [Abstract][Full Text] [Related]
7. The association of non-severe COVID-19 infection and progression to frailty among robust older veterans. Resendes NM; Bradley J; Tang F; Hammel IS; Ruiz JG J Nutr Health Aging; 2024 Aug; 28(8):100296. PubMed ID: 38901116 [TBL] [Abstract][Full Text] [Related]
8. Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves. Hammel IS; Tosi DM; Tang F; Pott H; Ruiz JG J Am Geriatr Soc; 2023 Dec; 71(12):3826-3835. PubMed ID: 37725480 [TBL] [Abstract][Full Text] [Related]
9. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Antonelli M; Penfold RS; Merino J; Sudre CH; Molteni E; Berry S; Canas LS; Graham MS; Klaser K; Modat M; Murray B; Kerfoot E; Chen L; Deng J; Österdahl MF; Cheetham NJ; Drew DA; Nguyen LH; Pujol JC; Hu C; Selvachandran S; Polidori L; May A; Wolf J; Chan AT; Hammers A; Duncan EL; Spector TD; Ourselin S; Steves CJ Lancet Infect Dis; 2022 Jan; 22(1):43-55. PubMed ID: 34480857 [TBL] [Abstract][Full Text] [Related]
10. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. Wu JT; La J; Branch-Elliman W; Huhmann LB; Han SS; Parmigiani G; Tuck DP; Brophy MT; Do NV; Lin AY; Munshi NC; Fillmore NR JAMA Oncol; 2022 Feb; 8(2):281-286. PubMed ID: 34854921 [TBL] [Abstract][Full Text] [Related]
11. Comparative Risks of Potential Adverse Events Following COVID-19 mRNA Vaccination Among Older US Adults. Harris DA; Hayes KN; Zullo AR; Mor V; Chachlani P; Deng Y; McCarthy EP; Djibo DA; McMahill-Walraven CN; Gravenstein S JAMA Netw Open; 2023 Aug; 6(8):e2326852. PubMed ID: 37531110 [TBL] [Abstract][Full Text] [Related]
13. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN BMJ; 2023 May; 381():e074521. PubMed ID: 37220941 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study. Chiew CJ; Premikha M; Chong CY; Wei WE; Ong B; Lye DC; Heng D; Lee VJ; Tan KB Lancet Infect Dis; 2023 Feb; 23(2):177-182. PubMed ID: 36182678 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022. Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M; Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801 [TBL] [Abstract][Full Text] [Related]
16. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193 [TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. Vo AD; La J; Wu JT; Strymish JM; Ronan M; Brophy M; Do NV; Branch-Elliman W; Fillmore NR; Monach PA JAMA Netw Open; 2022 Oct; 5(10):e2240037. PubMed ID: 36264571 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans. Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland. Kerr S; Vasileiou E; Robertson C; Sheikh A J Glob Health; 2022 Jul; 12():05025. PubMed ID: 35802764 [TBL] [Abstract][Full Text] [Related]
20. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]